This volume contains refereed papers by participants in the two weeks on Clinical Trials and one week on Epidemiology and the Environment held as part of the six weeks workshop on Statistics in the Health Sciences Applications at the Institute for Mathematics and its Applications (IMA) in the summer of 1997. Donald Berry was in charge of the weeks on clinical trials, and Elizabeth Halloran organized the week on epidemiology and the environment. The collection includes a major contribution from Jamie Robins, Andrea Rotnitzky, and Daniel Scharfstein on sensitivity analysis for selection bias and unmeasured confounding in missing data and causal and inference models. In another paper, Jamie Robins presents a new class of causal models called marginal structural models. Alan Hubbard, Mark van der Laan, and Jamie Robins present a methodology for consistent and efficient estimation of treatment-specific survival functions in observational settings. Brian Leroux, Xingye Lei, and Norman Breslow present a new mixed model for spatial dependence for estimating disease rates in small areas. Andrew Lawson and Allan Clark demonstrate Markov Chain Monte Carlo methods for clustering in spatial epidemiology. Colin Chen, David Chock, and Sandra Winkler present a simulation study examining confounding in estimation of the epidemiologic effect of air pollution. Dalene Stangl discusses issues in the use of reference priors and Bayes factors in analyzing clinical trials. Stephen George reviews the role of surrogate endpoints in cancer clinical trials.

This IMA Volume in Mathematics and its Applications STATISTICAL MODELS IN EPIDEMIOLOGY, THE ENVIRONMENT, AND CLINICAL TRIALS is a combined proceedings on "Design and Analysis of Clinical Trials" and "Statistics and Epidemiology: Environment and Health. " This volume is the third series based on the proceedings of a very successful 1997 IMA Summer Program on "Statistics in the Health Sciences. " I would like to thank the organizers: M. Elizabeth Halloran of Emory University (Biostatistics) and Donald A. Berry of Duke University (Insti tute of Statistics and Decision Sciences and Cancer Center Biostatistics) for their excellent work as organizers of the meeting and for editing the proceedings. I am grateful to Seymour Geisser of University of Minnesota (Statistics), Patricia Grambsch, University of Minnesota (Biostatistics); Joel Greenhouse, Carnegie Mellon University (Statistics); Nicholas Lange, Harvard Medical School (Brain Imaging Center, McLean Hospital); Barry Margolin, University of North Carolina-Chapel Hill (Biostatistics); Sandy Weisberg, University of Minnesota (Statistics); Scott Zeger, Johns Hop kins University (Biostatistics); and Marvin Zelen, Harvard School of Public Health (Biostatistics) for organizing the six weeks summer program. I also take this opportunity to thank the National Science Foundation (NSF) and the Army Research Office (ARO), whose financial support made the workshop possible. Willard Miller, Jr."

With just over half a decade passing since the first edition of the Handbook of Pediatric Cardiovascular Drugs was published, it remains the only book of its nature to provide health care practitioners with a tool to safely and consistently prescribe and administer cardiovascular drugs in children with cardiac disease. In this new edition, the editors have updated this important resource in collaboration with highly reputed authors. This pocket reference handbook remains tailored to help cardiovascular practitioners meet the daily challenges of caring for patients, from the newborn to the young adult, with cardiac disease. In addition to providing an extensive review of all cardiovascular medications, the Handbook of Pediatric Cardiovascular Drugs, 2nd Edition also discusses the information required to assist caregivers in their daily clinical practice. Physicians, fellows, residents, nurse practitioners, physician assistants, pharmacists, nurses and other practitioners alike will find this handbook to be an essential resource for drug therapy in complex and high-risk patients with acquired and congenital heart disease.